Eight analysts have recently updated their ratings on DexCom (NASDAQ:DXCM), with a mix of bullish and bearish sentiments. The average 12-month price target is $126.38, with a high of $150.00 and a low of $100.00, reflecting a slight decrease of 0.6%. Analysts from firms like Raymond James, Piper Sandler, and Wells Fargo have raised their price targets, while JP Morgan and Stifel have lowered theirs. DexCom, a company specializing in continuous glucose monitoring systems, has shown strong revenue growth but faces challenges with profitability and asset utilization. Its market capitalization is above industry average, indicating investor confidence.